Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07854652) titled 'BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia' on Sept. 27.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: The First Affiliated Hospital of Soochow University
Condition:
B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Intervention:
Drug: Ifupinostat Hydrochloride
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: September 1, 2026
Target Sample Size: 15
Countries of Recruitment:
China
To...